Purple Biotech LTD. (PPBT) SEC Filings — 2024
39 SEC filings for Purple Biotech LTD. (PPBT) in 2024.
Filings
- Purple Biotech Ltd. Updates Company Presentation — 6-K · Dec 6, 2024
- Purple Biotech Closes $2.8M ADS Offering — 6-K · Dec 5, 2024
- Purple Biotech Files 6-K with Purchase Agreement Details — 6-K · Dec 4, 2024
- Purple Biotech Raises $2.8M in Direct Offering — 6-K · Dec 3, 2024
- Purple Biotech Reports Positive Phase 2 Pancreatic Cancer Study Results — 6-K · Dec 2, 2024
- Purple Biotech Reports Q3 2024 Financial Results — 6-K · Nov 15, 2024
- Purple Biotech LTD. SC 13G/A Filing — SC 13G/A · Nov 14, 2024
- Purple Biotech Identifies Oncology Biomarker Linked to 79% PFS Reduction — 6-K · Nov 4, 2024
- Purple Biotech Presents CAPTN-3 Data at EORTC-NCI-AACR — 6-K · Oct 25, 2024
- Purple Biotech to Present CAPTN-3 Data at EORTC-NCI-AACR Symposium — 6-K · Oct 10, 2024
- Purple Biotech Ltd. Updates Company Presentation — 6-K · Oct 9, 2024
- Purple Biotech Regains Nasdaq Bid Price Compliance — 6-K · Oct 2, 2024
- Purple Biotech Reports Positive Phase 2 Data for Candida — 6-K · Sep 18, 2024
- Purple Biotech to Change ADS Ratio — 6-K · Sep 11, 2024
- Purple Biotech Ltd. Updates Company Presentation — 6-K · Aug 19, 2024
- Purple Biotech Reports Q2 2024 Financials and Highlights — 6-K · Aug 16, 2024
- Purple Biotech Ltd. Holds Annual Shareholder Meeting — 6-K · Aug 8, 2024
- Purple Biotech CFO Resigns — 6-K · Aug 5, 2024
- Purple Biotech Gets Nasdaq Bid Price Compliance Extension — 6-K · Jul 25, 2024
- Purple Biotech Ltd. Updates Company Presentation — 6-K · Jul 19, 2024
- Purple Biotech Files 6-K with Warrant and Placement Agent Forms — 6-K · Jul 2, 2024
- Purple Biotech Raises $2M from Warrant Exercise — 6-K · Jul 1, 2024
- Purple Biotech Reports Positive Phase 2 Pancreatic Cancer Study Results — 6-K · Jun 27, 2024
- Purple Biotech Sets August 8 Shareholder Meeting — 6-K · Jun 26, 2024
- Purple Biotech Lawsuit Dismissed by Court — 6-K · Jun 20, 2024
- Purple Biotech Ltd. Updates Company Presentation — 6-K · Jun 4, 2024
- Purple Biotech's CM24 Shows Improved Survival in Phase 2 Data — 6-K · Jun 3, 2024
- Purple Biotech Reports Q1 2024 Financial Results — 6-K · May 21, 2024
- Purple Biotech Updates Company Presentation — 6-K · May 2, 2024
- Purple Biotech's Pancreatic Cancer Study Accepted at ASCO 2024 — 6-K · Apr 25, 2024
- Purple Biotech to Present NT219 Oncology Data at AACR 2024 — 6-K · Mar 28, 2024
- Purple Biotech Reports Preclinical Proof of Concept — 6-K · Mar 14, 2024
- Purple Biotech Updates Company Presentation — 6-K · Mar 6, 2024
- Purple Biotech Ltd. Files 20-F Annual Report for Fiscal Year Ended December 31, 2023 — 20-F · Mar 5, 2024
- Purple Biotech Presents Phase 1 Cancer Data at ESMO TAT — 6-K · Feb 27, 2024
- Purple Biotech LTD. SC 13G Filing — SC 13G · Feb 14, 2024
- Purple Biotech Convenes SAB for NT219 Head & Neck Cancer Phase 2 Trial — 6-K · Feb 13, 2024
- Purple Biotech's NT219 Reaches Recommended Phase 2 Dose — 6-K · Feb 1, 2024
- Purple Biotech Gets Nasdaq Delisting Warning for Low Bid Price — 6-K · Jan 26, 2024